Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
•
HIV & AIDS
Would you consider using thalidomide for treating HIV-associated tuberculosis-IRIS in adult patients who have poor response or intolerance to corticosteroid therapy?
Related Questions
Do you routinely treat pregnant patients for latent tuberculosis or delay treatment until 2-3 months post-partum?
What is your approach to work up and management of a patient with advanced HIV and poor adherence to therapy presenting with dysphagia and fever?
Do you recommend to continue acyclovir to prevent HSV infection in an HIV patient with CD4 count more than 200 and with high viral load?
How do you balance diagnostic stewardship and high value cost-conscious care when working up a patient with newly diagnosed HIV/AIDS admitted to the ICU with shortness of breath who most likely has PJP pneumonia or cryptococcal infection but is at risk of multiple other pathogens?
Would you use immunotherapy in patients with HIV and a positive viral load?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
How do you approach the treatment of H. pylori infection in people living with HIV, considering the increased risk of antibiotic resistance and potential drug interactions with antiretroviral therapy?
Would you recommend switching from an integrase strand transfer inhibitor-based regimen to a different antiretroviral regimen, or would you instead add weight loss medications for a person with HIV experiencing weight gain that has not improved with lifestyle changes?
Which patients with NNRTI resistance mutations who wish to simplify their HIV antiretroviral regimens do you consider switching to cabotegravir/rilpivirine?
